Keyphrases
Non-small Cell Lung Cancer (NSCLC)
100%
Neoadjuvant Therapy
100%
High-dose Radiotherapy
100%
Chemoradiotherapy
66%
Median Time
66%
Overall Survival
66%
Concurrent Chemoradiotherapy
66%
High Dose
33%
Consecutive Patients
33%
Mortality Rate
33%
30-day Mortality
33%
Radiotherapy
33%
Etoposide
33%
Adenocarcinoma
33%
Cisplatin
33%
Clinical Benefit
33%
Progression-free Survival
33%
Chemoradiation
33%
Not Otherwise Specified
33%
High-dose Radiation
33%
IRB Approval
33%
Combined Modality Therapy
33%
Distant Failure
33%
Locoregional
33%
Regional Failure
33%
Lobectomy
33%
Pneumonectomy
33%
Pathological Complete Response
33%
90-day Mortality
33%
Chemoradiotherapy Followed by Surgery
33%
Distant Progression
33%
Nodal Upstaging
33%
Medicine and Dentistry
Drug Megadose
100%
Chemoradiotherapy
100%
Non Small Cell Lung Cancer
100%
Neoadjuvant Therapy
100%
Radiation Therapy
100%
Overall Survival
50%
Mortality Rate
25%
Adenocarcinoma
25%
Cisplatin
25%
Progression Free Survival
25%
Etoposide
25%
Pneumonectomy
25%
Lobectomy
25%
Chemoradiation Therapy
25%
Diseases
25%
Pharmacology, Toxicology and Pharmaceutical Science
Chemoradiation Therapy
100%
Non Small Cell Lung Cancer
100%
Overall Survival
40%
Mortality Rate
20%
Adenocarcinoma
20%
Cisplatin
20%
Progression Free Survival
20%
Etoposide
20%
Diseases
20%
Immunology and Microbiology
Drug Megadose
100%
Overall Survival
66%
Mortality Rate
33%
Progression Free Survival
33%